Low lean mass and chemotherapy toxicity risk in the elderly: the Fraction study protocol

Zara Steinmeyer, Stéphane Gérard, Thomas Filleron, Stéphanie Lozano, Delphine Brechemier, Gabor Abellan Van Kan, Loic Mourey, Laurence Cristol-Dalstein, Laure De Decker, Yves Rolland, Laurent Balardy, Zara Steinmeyer, Stéphane Gérard, Thomas Filleron, Stéphanie Lozano, Delphine Brechemier, Gabor Abellan Van Kan, Loic Mourey, Laurence Cristol-Dalstein, Laure De Decker, Yves Rolland, Laurent Balardy

Abstract

Background: Half of cancer cases occur in patients aged 70 and above. Majority of older patients are eligible for chemotherapy but evidence for treating this population is sparse and severe toxicities affect more than half of them. Determining prognostic biomarkers able to predict poor chemotherapy tolerance remains one of the major issues in geriatric oncology. Ageing is associated with body composition changes (increase of fat mass and loss of lean mass) independently of weight-loss. Previous studies suggest that body composition parameters (particularly muscle mass) may predict poor chemotherapy tolerance. However, studies specifically including older adults on this subject remain sparse and the majority of them study body composition based on computed tomography (CT) scanner (axial L3 section) muscle mass estimation. This method is to date not validated in elderly cancer patients.

Methods: This trial (Fraction) will evaluate the discriminative ability of appendicular lean mass measured by dual-energy X-ray absorptiometry (DXA) to predict severe toxicity incidence in older cancer-patients treated with first-line chemotherapy. DXA is considered the gold standard in body composition assessment in older adults. Patient's aged ≥70 diagnosed with solid neoplasms or lymphomas at a locally advanced or metastatic stage treated for first-line chemotherapy were recruited. Patients completed a pre-chemotherapy assessment that recorded socio-demographics, tumor/treatment variables, laboratory test results, geriatric assessment variables (function, comorbidity, cognition, social support and nutritional status), oncological risk scores and body composition with DXA. Appendicular lean mass was standardized using evidence based international criteria. Participants underwent short follow-up geriatric assessments within the first 3 months, 6 months and a year after inclusion. Grade 3 to 5 chemotherapy-related toxicities, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) were assessed at each chemotherapy cycle.

Discussion: The finding that body composition is associated with poor tolerance of chemotherapy could lead to consider these parameters as well as improve current decision-making algorithms when treating older adults.

Trial registration: ClinicalTrials.gov Identifier: NCT02806154 registered on October 2016.

Keywords: Aged; Appendicular lean mass; Cancer; Chemotherapy toxicity; Dual energy X-ray absorptiometry; Low lean mass; Muscle mass.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Assessment and follow up study scheme

References

    1. WHO Cancer. . Accessed 12 Jan 2018.
    1. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–2726. doi: 10.1001/jama.291.22.2720.
    1. Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L, et al. Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(32):3826–3833. doi: 10.1200/JCO.2015.63.0319.
    1. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer. J Clin Oncol. 2014;32(24):2595–2603. doi: 10.1200/JCO.2013.54.8347.
    1. Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. Leuk Res. 2014;38(3):275–283. doi: 10.1016/j.leukres.2013.12.018.
    1. Puts MTE, Santos B, Hardt J, Monette J, Girre V, Atenafu EG, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(2):307–315. doi: 10.1093/annonc/mdt386.
    1. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–3386. doi: 10.1002/cncr.26646.
    1. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(25):3457–3465. doi: 10.1200/JCO.2011.34.7625.
    1. Gérard S, Bréchemier D, Lefort A, Lozano S, Abellan Van Kan G, Filleron T, et al. Body composition and anti-neoplastic treatment in adult and older subjects - a systematic review. J Nutr Health Aging. 2016;20(8):878–888. doi: 10.1007/s12603-015-0653-2.
    1. Prado CMM, Maia YLM, Ormsbee M, Sawyer MB, Baracos VE. Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics. Anticancer Agents Med Chem. 2013;13(8):1197–1203. doi: 10.2174/18715206113139990322.
    1. Schmid SM, Eichholzer M, Bovey F, Myrick ME, Schötzau A, Güth U. Impact of body mass index on compliance and persistence to adjuvant breast cancer therapy. Breast Edinb Scotl. 2012;21(4):487–492. doi: 10.1016/j.breast.2011.11.005.
    1. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(9):1649–1657. doi: 10.3109/10428194.2010.494315.
    1. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–763. doi: 10.1093/oxfordjournals.aje.a009520.
    1. Prado CMM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, et al. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2014;39(6):693–698. doi: 10.1139/apnm-2013-0403.
    1. Prado CMM, Antoun S, Sawyer MB, Baracos VE. Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity. Curr Opin Clin Nutr Metab Care. 2011;14(3):250–254. doi: 10.1097/MCO.0b013e3283455d45.
    1. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181. doi: 10.1016/S1053-4296(03)00031-6.
    1. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc déc. 1983;31(12):721–727. doi: 10.1111/j.1532-5415.1983.tb03391.x.
    1. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85–M94. doi: 10.1093/geronj/49.2.M85.
    1. Fayers P, Bottomley A. EORTC Quality of Life Group, Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38(Suppl 4):S125–S133. doi: 10.1016/S0959-8049(01)00448-8.
    1. Martinez-Tapia C, Paillaud E, Liuu E, Tournigand C, Ibrahim R, Fossey-Diaz V, et al. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. Eur J Cancer. 2017;83:211–219. doi: 10.1016/j.ejca.2017.06.027.
    1. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622–626. doi: 10.1111/j.1532-5415.1968.tb02103.x.
    1. Yesavage JA. Geriatric depression scale. Psychopharmacol Bull. 1988;24(4):709–711.
    1. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of adl: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–919. doi: 10.1001/jama.1963.03060120024016.
    1. Vellas B, Villars H, Abellan G, Soto ME, Rolland Y, Guigoz Y, et al. Overview of the MNA--its history and challenges. J Nutr Health Aging. 2006;10(6):456–463.
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(27):3059–3068. doi: 10.1200/JCO.2013.54.8800.
    1. Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: the mini nutritional assessment as part of the geriatric evaluation. Nutr Rev. 1996;54(1 Pt 2):S59–S65.
    1. Obuchowski NA, Lieber ML. Confidence intervals for the receiver operating characteristic area in studies with small samples. Acad Radiol août. 1998;5(8):561–571. doi: 10.1016/S1076-6332(98)80208-0.
    1. Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B Stat Methodol. 2005;67(2):301–320. doi: 10.1111/j.1467-9868.2005.00503.x.
    1. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc B. 1996;58:267–288.
    1. Zemmour C, Bertucci F, Finetti P, Chetrit B, Birnbaum D, Filleron T, et al. Prediction of early breast cancer metastasis from DNA microarray data using high-dimensional cox regression models. Cancer Inform. 2015;14(Suppl 2):129–138.
    1. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36. doi: 10.1148/radiology.143.1.7063747.
    1. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. doi: 10.1046/j.1365-2125.2003.02007.x.
    1. Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2008;33(5):997–1006. doi: 10.1139/H08-075.
    1. Kilgour RD, Cardiff K, Rosenthall L, Lucar E, Trutschnigg B, Vigano A. Use of prediction equations to determine the accuracy of whole-body fat and fat-free mass and appendicular skeletal muscle mass measurements from a single abdominal image using computed tomography in advanced cancer patients. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2016;41(1):70–75. doi: 10.1139/apnm-2015-0068.
    1. Pritchard JE, Nowson CA, Strauss BJ, Carlson JS, Kaymakci B, Wark JD. Evaluation of dual energy X-ray absorptiometry as a method of measurement of body fat. Eur J Clin Nutr. 1993;47(3):216–228.
    1. Lohman T, Wang Z, Going SB. Human Body Composition. Human Kinetics. 2005. p. 544.
    1. Institut national du cancer . Les cancers en France. Edition 2015 2016.
    1. Bretagne M, Jouinot A, Durand JP, Huillard O, Boudou Rouquette P, Tlemsani C, et al. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. Cancer Chemother Pharmacol. 2017;80(1):45–53. doi: 10.1007/s00280-017-3326-5.
    1. Sjøblom B, Benth JŠ, Grønberg BH, Baracos VE, Sawyer MB, Fløtten Ø, et al. Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung Cancer. Clin Lung Cancer. 2017;18(2):e129–e136. doi: 10.1016/j.cllc.2016.09.008.
    1. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, Antoun S. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr. 2010;91(4):1133S–1137S. doi: 10.3945/ajcn.2010.28608C.
    1. Miya T, Goya T, Fujii H, Ohtsu T, Itoh K, Igarashi T, et al. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Investig New Drugs. 2001;19(1):61–67. doi: 10.1023/A:1006456717846.
    1. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(9):2590–2611. doi: 10.1200/JCO.1996.14.9.2590.
    1. Miller AA. Body surface area in dosing anticancer agents: scratch the surface! J Natl Cancer Inst. 2002;94(24):1822–1823. doi: 10.1093/jnci/94.24.1822.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する